Furthermore, our results are limited to available SNPs captured in the exome database, and data of several other pharmacogenomic variants associated with efficacy and toxicity of anti-cancer drugs, such as those in genes CYP2D6, CYP2C9, NUT15 and TPMT, composed of predominantly haplotypic and intronic variants were not available. The gene discussed is CYP2C9; the disease is cancer.